Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02023996 · ClinicalTrials.gov registry record · NA
PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer
A NA study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 42
- Enrollment target
NCT02023996: Completed NA study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02023996 is a NA study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02023996, a NA study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 42 participants
- Enrollment target
Study Summary
The purpose of the first group (Group 1) was to find the optimal time for taking pictures after injection of 89Zr-DFO-trastuzumab, to see how long it stayed in the blood, and to see how well it was tolerated. From what the investigators have learned from Group 1, patients in Group 2 no longer need serial scans or serial blood draws. This study is based on a cohort expansion. All data is appropriately reported as there is only one study cohort
Interventions
- RADIATION 89Zr-DFO-trastuzumab
- DEVICE PET imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2013-12 |
| Est. Completion | 2023-06-27 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02023996
The ClinicalTrials.gov registry entry for NCT02023996 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 89Zr-DFO-trastuzumab is the first listed.
NCT02023996 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02023996 about?
NCT02023996 is a clinical study titled "PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer". The purpose of the first group (Group 1) was to find the optimal time for taking pictures after injection of 89Zr-DFO-trastuzumab, to see how long it stayed in the blood, and to see how well it was tolerated. From what the investigators have learned from Group 1, patients in Group 2 no longer need s...
What is the current status of trial NCT02023996?
This trial is currently completed. It is a NA study. The enrollment target is 42 participants. The study started on 2013-12. Estimated completion is 2023-06-27.
What interventions are being tested in trial NCT02023996?
The interventions under investigation include: 89Zr-DFO-trastuzumab (RADIATION), PET imaging (DEVICE).
Who is sponsoring clinical trial NCT02023996?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.